Dandona, P., Chaudhuri, A
A growing body of research suggests that GLP-1 receptor agonists can improve several markers tied to cardiovascular risk, including blood pressure, cholesterol levels, blood sugar control, and inflammation
When published, these papers will be extremely influential in the field of addiction
The p-values reported in all figures come from the hypothesis testing for the Kaplan-Meier survival curves and were conducted using the log-rank test
Were comparing results from separate trials with different participants, which has limitations: Different inclusion/exclusion criteria Different trial durations (68 vs 72 weeks) Different geographic populations Different lifestyle intervention protocols What Doctors Say: Most weight loss physicians report that both medications are highly effective